IP Library Granted Patent US 10,279,075
Granted Patent B2
US 10,279,075 · App. 15/337,427 · Granted May 7, 2019

Preparations containing hepatocyte growth factor and hyaluronic acid, and methods of making and using same

Inventor: Howard P. Walthall, Jr. (Birmingham, AL)
Assignee: NUTECH MEDICAL, INC.
A61L27/20A61K8/64A61K8/735A61K38/1833A61L27/54A61L27/56A61Q19/08A61K2800/91A61L2300/414A61L2400/06A61L2430/02A61L2430/06A61L2430/10A61L2430/24A61L2430/32A61L2430/34A61L2430/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,279,075
App. No.
15/337,427
Granted
May 7, 2019
Kind
B2
Abstract

Preparations containing hepatocyte growth factor (HGF) and hyaluronic acid (HA) and methods of making and using same. The HGF and HA preparations can be prepared together in solution as an injectable fluid without gelatinization, or impregnated within a porous hydrophilic matrix material with, or without, cross-linking of the HA with the matrix material. The preparations can be used as a dermal filler or to generate and promote healing of cartilage, vertebral discs, connective tissues such as tendons and ligaments and bone in vivo.

Claims (7)

1. A composition for regenerating damaged or defective tissue comprising:

a porous matrix,

hyaluronic acid (HA) cross-linked in situ within the porous matrix in the presence of cross-linking heavy chains of inter-alpha inhibitor and Tumor Necrosis Factor Stimulating Gene-6, and hepatocyte growth factor (HGF),

wherein there is limited or no chemical cross-linking of the HA with the porous matrix.

2. The composition of claim 1 wherein the HA is cross-linked in situ within the porous matrix by soaking the porous matrix with the HA, the cross-linking heavy chains of inter-alpha inhibitor and Tumor Necrosis Factor Stimulating Gene 6.

3. The composition of claim 1 wherein the HGF is added during cross-linking of HA in situ within the porous matrix.

4. The composition of claim 1 , wherein the HGF is added by soaking the porous matrix in HGF after cross-linking of HA in situ within the porous matrix.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2026
From: FIRST-CITIZENS BANK & TRUST COMPANY
To: PRIME MERGER SUB, LLC
Reel/Frame 075619/0612 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2026
From: FIRST-CITIZENS BANK & TRUST COMPANY
To: ORGANOGENESIS HOLDINGS INC.; PRIME MERGER SUB, LLC
Reel/Frame 075619/0630 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 6, 2021
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 057112/0703 →
SECURITY INTEREST Recorded Aug 6, 2021
From: ORGANOGENESIS INC.; PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 057108/0846 →
MERGER AND CHANGE OF NAME Recorded Apr 11, 2019
From: NUTECH MEDICAL, INC.; PRIME MERGER SUB, LLC
To: PRIME MERGER SUB, LLC
Reel/Frame 048860/0093 →
SECURITY INTEREST Recorded Jun 19, 2018
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 046131/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2018
From: WALTHALL, HOWARD P., JR.
To: NUTECH SPINE, INC.
Reel/Frame 045238/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2017
From: NUTECH SPINE, INC.
To: NUTECH MEDICAL, INC.
Reel/Frame 041930/0361 →
SECURITY INTEREST Recorded Mar 28, 2017
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 041767/0804 →
Continuity (3)
Continuation 14211929 · Mar 14, 2014
Provisional Application 61790075 · Mar 15, 2013
Related Publication 20170043054A1 · Feb 16, 2017